openPR Logo
Press release

Investigation announced for Long-Term Investors in shares of Catalent, Inc. (NYSE: CTLT) over potential Wrongdoing

05-20-2023 02:52 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of current long term investors in Catalent, Inc. (NYSE: CTLT) shares.

An investigation on behalf of current long term investors in Catalent, Inc. (NYSE: CTLT) shares.

An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Catalent, Inc.

Investors who are current long term investors in Catalent, Inc. (NYSE: CTLT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NYSE: CTLT stocks follows a lawsuit filed against Catalent, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NYSE: CTLT stocks, concerns whether certain Catalent, Inc. directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the District of New Jersey the plaintiff alleges that statements made by the defendants were materially false and misleading when made because they misrepresented or failed to disclose the following adverse facts, which were known to Defendants or recklessly disregarded by them: (a) Catalent materially overstated its revenue and earnings by prematurely recognizing revenue in violation of U.S. Generally Accepted Accounting Principles ("GAAP"); (b) Catalent had material weaknesses in its internal control over financial reporting related to revenue recognition; (c) Catalent falsely represented demand for its products while it knowingly sold more product to its direct customers than could be sold to healthcare providers and end consumers; (d) Catalent disregarded regulatory rules at key production facilities in order to rapidly produce excess inventory that was used to pad the Company's financial results through premature revenue recognition in violation of GAAP and/or stuffing its direct customers with this excess inventory; and (e) as a result of the foregoing, Defendants lacked a reasonable basis for their positive statements about the Company's financial performance, outlook, and regulatory compliance between August 30, 2021 and October 31, 2022.

Those who purchased shares of Catalent, Inc. (NYSE: CTLT) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Long-Term Investors in shares of Catalent, Inc. (NYSE: CTLT) over potential Wrongdoing here

News-ID: 3060878 • Views:

More Releases from Shareholders Foundation

Biohaven Ltd. (NYSE: BHVN) Investor Alert: Deadline in Lawsuit on September 12, 2025
Biohaven Ltd. (NYSE: BHVN) Investor Alert: Deadline in Lawsuit on September 12, …
A deadline is coming up on September 12, 2025in the lawsuit filed for certain investors of Biohaven Ltd. (NYSE: BHVN) over alleged securities laws violations by Biohaven Ltd. Investors who purchased shares of Biohaven Ltd. (NYSE: BHVN) have certain options and there are strict and short deadlines running. Deadline: September 12, 2025. NYSE: BHVN stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. According to the
Investigation announced for Long-Term Investors in shares of West Pharmaceutical Services, Inc. (NYSE: WST) over potential Wrongdoing
Investigation announced for Long-Term Investors in shares of West Pharmaceutical …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of West Pharmaceutical Services, Inc.. Investors who are current long term investors in West Pharmaceutical Services, Inc. (NYSE: WST) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in (NYSE: WST stocks follows a lawsuit filed
Investigation announced for Long-Term Investors in Open Lending Corporation (NASDAQ: LPRO) over potential Wrongdoing
Investigation announced for Long-Term Investors in Open Lending Corporation (NAS …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Open Lending Corporation. Investors who are current long term investors in Open Lending Corporation (NASDAQ: LPRO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: LPRO stocks follows a lawsuit filed against Open
Investigation announced for Long-Term Investors in shares in BigBear.ai Holdings, Inc. (NYSE: BBAI)
Investigation announced for Long-Term Investors in shares in BigBear.ai Holdings …
An investigation on behalf of current long-term investors in shares of BigBear.ai Holdings, Inc. (NYSE: BBAI) concerning potential breaches of fiduciary duties by certain directors and officers of BigBear.ai Holdings, Inc. was announced. Investors who are current long term investors in BigBear.ai Holdings, Inc. (NYSE: BBAI) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm

All 5 Releases


More Releases for Catalent

Softgel Capsule Market Projected to Witness Robust Expansion - Catalent, Aenova
Softgel Capsule Market Insights Softgel Capsule Market is estimated to be valued at USD 7,850.0 Mn in 2025 and is expected to reach USD 12,118.8 Mn in 2032, exhibiting a compound annual growth rate (CAGR) of 6.4% from 2025 to 2032. Coherent Market Insights has published a new comprehensive analysis on the Softgel Capsule Market (2025-2032), focusing on critical transformations in the U.S. healthcare environment. This report highlights essential metrics including market
Orodispersible Tablets Market: Patient-Centric Innovations in Pharmaceuticals | …
IMR posted new studies guide on Orodispersible Tablets Market Insights with self-defined Tables and charts in presentable format. In the Study you may locate new evolving Trends, Drivers, Restraints, Opportunities generated via targeting market related stakeholders. The boom of the Orodispersible Tablets marketplace became specifically driven with the aid of the growing R&D spending internationally. Some of the Top Leading Key Players: Actavis (Ireland), AstraZeneca (United Kingdom), Bayer AG (Germany), Catalent,
Vaccine Contract Manufacturing Market is Going to Boom | Ajinomoto, Merck, Catal …
Archive Market Research published a new research publication on "Vaccine Contract Manufacturing Market Insights, to 2032" with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Vaccine Contract Manufacturing market was mainly driven by the increasing R&D spending across the world. Some of the key players
Sustainable Pharmaceutical Packaging Market Is Booming Worldwide | Catalent,Gerr …
The "Sustainable Pharmaceutical Packaging Market" intelligence report, just published by USD Analytics Market, covers a micro-level study of important market niches, product offers, and sales channels. to determine market size, potential, growth trends, and competitive environment, the Sustainable Pharmaceutical Packaging Market provides dynamic views. Both primary and secondary sources of data were used to generate the research, which has both qualitative and quantitative depth. Several of the major figures the
Polymer Prefilled Syringe Market | BD, Baxter BioPharma Solution, Catalent, Gerr …
The global polymer prefilled syringe market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the polymer prefilled syringe market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants. From the perspective of market dynamics, this report explores the factors driving the growth
Vaccine Contract Manufacturing Market is Growing Rapidly with Catalent, Moderna
Contract manufacturing is a complex process involved in producing vaccine products. This type of production usually involves the manufacturing of vaccines in a single step. Contract manufacturers usually produce vaccines at their facilities; however, some contract manufacturers also service the field through the provision of workspace and by taking care of the closing storage and final disposition of finished products. Some contract manufacturers specialize in the manufacture of one or